Print | Email | Share | Comments (0)

Is This the ACCORD Study’s Silver Lining?

Byetta Seems to Prolong Lifespan

Aug 14, 2008

While Lilly and Amylin are intrigued by the findings, they realize that any study designed to confirm Byetta’s usefulness as a life extender would take years of study involving thousands of participants.

Several months ago researchers suspended work on the landmark ACCORD (Action to Control Cardiovascular Risk in Diabetes) study, which tracked 10,251 type 2s, some of them undergoing very tight control of their blood sugar levels.

The study subjected participants to a rigorous combination of drug therapy, exercise, and cholesterol and blood pressure control to drive their A1c’s down to 6% or below. The expectation was that tight blood sugar control would lower vascular inflammation and, therefore, the risk of heart attack.

But ACCORD’s sponsor, the National Heart, Lung, and Blood Institute, suspended the study when it found that the participants under strict control were dying at a statistically higher rate from cardiovascular problems than participants who were not under tight control.

Now, several months later, it appears that one of the bright spots in the study was the discovery that ACCORD participants who took Byetta during the study had a 75 percent lower chance of dying than patients who were taking other diabetic drugs.

That’s the statistic reported at the recent ADA annual conference in San Francisco by Dr. Michael Miller, the ACCORD trial’s lead statistician and a professor of biostatistics at Wake Forest University in Winston-Salem, North Carolina.

However, said Dr. Miller, the ACCORD participants who were taking Byetta tended to be healthier than other study participants, so their lower mortality rate may have been the result of their better health rather than a consequence of taking Byetta.

Still, Dr. Miller’s remarks surprised the powers that be at Byetta’s co-marketers, Eli Lilly and Amylin. While the drug, which controls the amount and release of glucose in the body, does have beneficial side effects that can boost cardiovascular health, such as weight loss and appetite control, no one has previously claimed any life-extending powers for it.

About 250,000 people nationwide take Byetta, which is injected twice daily. Introduced in 2005, the drug now earns about $700 million per year. A once-weekly version is now in Phase 3 trials under FDA oversight.

Categories: A1c Test, Blood Sugar, Diabetes, Diabetes, Heart Care & Heart Disease, Research, Type 2 Issues, Type 2 Medications

Comments

Add your comments about this article below. You can add comments as a registered user or anonymously. If you choose to post anonymously your comments will be sent to our moderator for approval before they appear on this page. If you choose to post as a registered user your comments will appear instantly.

When voicing your views via the comment feature, please respect the Diabetes Health community by refraining from comments that could be considered offensive to other people. Diabetes Health reserves the right to remove comments when necessary to maintain the cordial voice of the diabetes community.

For your privacy and protection, we ask that you do not include personal details such as address or telephone number in any comments posted.

Don't have your Diabetes Health Username? Register now and add your comments to all our content.

Have Your Say...

Registered User Anonymous

Your Name:	Your Email:	X

Recipient's Name:	Recipient's Email:

Your Chosen Username:	Your Email Address:

Chosen Password:	Confirm Password:

Email to a Friend

Is This the ACCORD Study’s Silver Lining?

You May Also Be Interested In...

Comments

Register...

Have Your Say...

Diabetes Health

Topics

Topics

Topics

Diabetes Health Medical Disclaimer

Comment: